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Background: Cyclin-dependent kinase 5 (Cdk5) is a unique member of the serine/threonine kinase family. This
kinase plays an important role in neuronal development, and deregulation of its activity leads to neurodegenerative
disorders. Cdk5 also serves an important function in the regulation of nociceptive signaling. Our previous studies
revealed that the expression of Cdk5 and its activator, p35, is upregulated in nociceptive neurons during peripheral
inflammation. The aim of the present study was to characterize the involvement of Cdk5 in orofacial pain. Since
mechanical hyperalgesia is the distinctive sign of many orofacial pain conditions, we adapted an existing orofacial
stimulation test to assess the behavioral responses to mechanical stimulation in the trigeminal region of the
transgenic mice with either reduced or increased Cdk5 activity.
Results: Mice overexpressing or lacking p35, an activator of Cdk5, showed altered phenotype in response to
noxious mechanical stimulation in the trigeminal area. Mice with increased Cdk5 activity displayed aversive
behavior to mechanical stimulation as indicated by a significant decrease in reward licking events and licking time.
The number of reward licking/facial contact events was significantly decreased in these mice as the mechanical
intensity increased. By contrast, mice deficient in Cdk5 activity displayed mechanical hypoalgesia.
Conclusions: Collectively, our findings demonstrate for the first time the important role of Cdk5 in orofacial
mechanical nociception. Modulation of Cdk5 activity in primary sensory neurons makes it an attractive potential
target for the development of novel analgesics that could be used to treat multiple orofacial pain conditions.
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Orofacial pain affects millions of people worldwide. It is
characterized by throbbing, sharp or burning pain in the
head, neck, face, mouth, gums or teeth. Epidemiological
studies indicate that orofacial pain occurs in approxi-
mately 10% of the adult population [1], and women are
more often affected than men by a ratio of 2:1 [2]. Oro-
facial pain episodes are usually very debilitating for
the patient. However, relatively few studies are focused
on characterizing orofacial pain, particularly due to the
limited number of animal models available to study
nociception in the trigeminal region. Most of these
models have been adapted from those used for studying* Correspondence: ak40m@nih.gov
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distribution, and reproduction in any mediumperipheral pain and are primarily based on the induction
of inflammation by the administration of nociceptive
agents, such as complete Freund’s adjuvant [3,4], carra-
geenan [5,6], and formalin [7-10]. Other models are
based on the direct damage to a nerve (cutting, ligating,
or crushing) [11-14]. These models suffer from certain
limitations, such as variation in subjective observation,
inability to escape from the noxious stimulus, and
induction of the stress in a test animal. The recently
reported operant behavioral assay using a reward-
conflict paradigm wherein a test animal can decide
between receiving a reward or escaping an aversive
stimulus present new perspectives on measuring pain in
the orofacial region [15-18].
There is accumulating evidence that protein kinases are
involved in mediating several types of pain. Cdk5 is a
serine/threonine kinase widely distributed in different
mammalian tissues, but its kinase activity is observedntral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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of its activators, p35 and p39. Cdk5 plays important roles
in many vital processes, including brain development and
function, neuronal migration, neurotransmitter release,
cell adhesion and survival, drug addiction, learning, mem-
ory [19-23], and also in many non-neuronal functions
[24-26]. Cdk5 knockout mice are embryonic lethal with
numerous lesions in the central nervous system [27].
Efforts to delineate molecular roles of Cdk5 in vivo led to
the generation of mice overexpressing [28] or lacking [29]
p35, an activator of Cdk5. Recently, we and others discov-
ered that Cdk5 activity regulates peripheral pain signaling,
and that it is required for the basal responses to noxious
heat [30,31]. The p35 knockout mice (with residual Cdk5
activity) showed delayed responses to painful thermal
stimulation (hypoalgesia), whereas mice overexpressing
p35 (with significantly increased Cdk5 activity) were more
sensitive to painful thermal stimulation showing hyper-
algesia. Moreover, we have identified that the expression
of p35, as well as Cdk5 kinase activity, is present in the
dorsal root ganglia and trigeminal ganglia neurons, and
both are significantly increased upon the induction of
peripheral inflammation [32]. Furthermore, nociceptor-
specific Cdk5 conditional knockout mice developed
hypoalgesia associated with reduced phosphorylation of
the TRPV1 channel [30].
The goal of the current study was to evaluate the
role of Cdk5 in orofacial mechanosensation and to
characterize the behavioral changes of mice lacking or
overexpressing p35 using adapted orofacial stimulation
test (Additional file 1).
Results
Cdk5 activity in transgenic p35 (Tgp35) and p35 knockout
(p35−/−) mice
We initially examined the expression and activity of
Cdk5/p35 in the trigeminal ganglia, brainstem, and
brain of mice that overexpress or lack p35. Analysis
of the Tgp35 mice revealed a significant increase in
p35 mRNA (Figure 1A) as well as in p35 protein levels
(Figure 1B). There was a three-fold increase in Cdk5 activ-
ity (Figure 1C) in the trigeminal ganglia of Tgp35 mice
compared with the wild-type (WT) mice (p < 0.001). The
Tgp35 mice also showed a significant increase in p35
mRNA and protein levels as well as in Cdk5 activity in
brainstem and in brain (Figure 1A-C). The analysis of the
p35−/− mice showed almost undetectable p35 mRNA and
protein levels (Figure 2A and B) and significantly de-
creased Cdk5 activity (Figure 2C) in tissue homogenates
from the trigeminal ganglia, brainstem, and brain, as com-
pared to controls (p < 0.001). The p35 expression levels
and Cdk5 activity correlated with the mouse genotype,
thus confirming that the p35 level is the limiting factor for
the Cdk5 activity [28].Normal motor coordination and locomotion in Tgp35 and
p35−/− mice
Having established the p35 expression levels and the
Cdk5 activity in Tgp35 and p35−/− mice, we determined
whether this difference in expression and activity of
Cdk5/p35 could affect the motor coordination and loco-
motion of these genetically modified animals. We did
not observe any motor deficit using the acceleration test
with rotarod when the rotation was set to accelerate
from 4 to 40 rpm during the defined period of time. The
average latency to drop from the cylinder was 269 sec-
onds in Tgp35 and 274 seconds in wild-type FVBN con-
trol mice, respectively (Additional file 2A). Similarly, no
significant difference in the fall latency was observed in
p35−/− mice (average latency 253 seconds in p35−/−
mice and 256 seconds in the wild-type C57 controls)
(Additional file 2A). There were no significant differ-
ences in the fall latency during the testing using the con-
stant rotation speed. The p35−/−, Tgp35, and their
respective, wild-type controls showed no motor deficits
as evident from the mean time spent on the rotarod
(Additional file 2B).
Normal anxiety level and exploratory behavior in Tgp35
and p35−/− mice
Before performing the orofacial operant assay on these
mice, we also assessed anxiety, exploratory activity, and
stereotypical behavioral using the open-field test. Neither
horizontal (Additional file 2C) or vertical (Additional file
2D) activity was affected in the p35−/− or Tgp35 mice,
in comparison to the control mice. Since the middle of a
non-familiar arena is anxiogenic for rodents, anxiety was
studied by analyzing the time spent and total distance
travelled in the middle of the cage. There were no sig-
nificant differences in the time spent in the center of
the cage as well as the center distance travelled by
the Tgp35 and their littermate controls (Additional
file 3A), and the p35−/− and wild-type C57 mice con-
trols (Additional file 4A). There were also no significant
changes in the stereotypical behavioral (Additional file
3B and Additional file 4B) or time spent at the different
corners of the activity cage (Additional file 3C and
Additional file 4C), indicating that the difference in the
p35 levels did not cause any change in anxiety or ex-
ploratory behavior of the mice.
Normal baseline behavior in orofacial operant assay
It was previously reported that the reward conflict para-
digm (using parameters such as reward licking events,
facial contact events, and facial contact duration) could
serve as a characteristic marker of pain in the orofacial
area [15,16]. In the mouse orofacial operant assay that
we report here, the number of attempts the test mouse
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Figure 1 (See legend on next page.)
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Figure 1 Analysis of the p35 expression profile in transgenic p35 (Tgp35) mice. The p35 expression levels and Cdk5 activity in the
trigeminal ganglia, brainstem, and brain of the transgenic p35 mice: (A) q-PCR analysis revealed significantly enhanced levels of p35 mRNA
in the trigeminal ganglia, brainstem, and the brain of the Tgp35 mice. Each data set was normalized to the expression seen in control wild-type
animals. The results obtained from four different animals are expressed as mean ± SEM and analyzed by an unpaired t-test (***p < 0.001). (B)
Representative Western blots showing p35 protein levels from Tgp35 tissue lysates together with corresponding densitometric analysis. Data
were normalized to the levels of p35 in wild-type controls, and are presented as mean ± SEM (unpaired t-test, ***p < 0.001). (C) Cdk5 activity in
the trigeminal ganglia, brainstem, and the brain of the Tgp35 mice. The data are presented as mean ± SEM and analyzed by an unpaired
t-test (***p < 0.001).
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this behavioral testing. Naïve animals were initially
trained to access the reward through the drinking win-
dow with an innocuous module. During the baseline
measurements, the Tgp35 and WT FVBN control mice
did not show any aversive behavior, and there was no
difference in the number of beam breaks and time the
animals spent with the licking recorded (Figure 3A).
After the completion of five different training sessions,
we observed the effects of the mechanical stimuli on
orofacial outcome measures.
Mechanical hyperalgesia in Tgp35 mice
In the presence of mechanical stimulators, the Tgp35
mice showed aversive behavior to mechanical stimuli as
indicated by a decrease in the number of attempts to
access the reward and the contact time compared to
the WT FVBN mice. The Tgp35 mice exhibited signifi-
cant mechanical hyperalgesia when subjected to orofa-
cial stimulation using plates with either 6 + 6 wires
(Figure 3B), 9 + 9 wires (Figure 3C), or 13 + 13 wires
(Figure 3D). The Tgp35 mice made significantly fewer at-
tempts to acquire the reward and spent much less time
licking the reward compared to the wild-type controls
(p < 0.001). The mechanical hyperalgesia caused by the
plates with the highest number of wires produced a
significantly lower reward intake as well as reduction in
the licking time, compared to the plates with the lower
numbers of the wires. We determined that the specific
behavioral changes between the Tgp35 and the wild-type
mice in the licking episodes were caused by the induc-
tion of nociception in the trigeminal area (Figure 3A-D).
Mechanical hypoalgesia in p35 knockout mice
Similar to the Tgp35 mice, there were no changes in
the baseline reward licking paradigm in the p35−/−
mice compared with the wild-type C57 control mice
(Figure 4A). However, we found that the p35−/− mice
displayed a significant mechanical hypoalgesia as com-
pared to the wild-type mice when tested with the plate
containing 6 + 6 wires (Figure 4B; p < 0.001). An add-
itional noxious stimulus caused a significant decrease in
the number of attempts to get the reward and time
spent licking reward by the wild-type control micecompared to the p35−/− mice (Figure 4C; p < 0.001).
The most obvious difference was noticed using the plate
with the highest number of the wires. The wild-type
mice spent only 1.7 seconds licking, whereas the p35−/−
mice licked for more than 13 seconds, indicating much
lower pain sensation in the p35−/− mice (Figure 4D;
p < 0.001). The number of attempts and the licking time
decreased significantly in the case of the wild-type mice
over the entire test period. However, there were no
changes in the licking patterns of the p35−/− mice after
inducing the mild pain, and more obvious changes were
observed inducing more painful conditions. In compar-
ing the wild-type and the p35−/− mice, there were also
clear changes in the licking pattern episodes caused by
different nociceptive stimulation (Figure 4A-D).
Discussion
The present study shows that Cdk5 has an important
role in orofacial pain signaling, and that this kinase is
associated with mechanical nociception in the mouse
vibrissal pad. We utilized two sets of mice with signifi-
cantly altered Cdk5 activity to confirm its association
with orofacial pain. Both p35 knockout (with residual
Cdk5 activity) and transgenic p35 (with significantly in-
creased Cdk5 activity) mice depicted an altered response
towards the mechanical stimulation. When tested with
mechanical stimuli, the mice lacking the p35 gene
showed hypoalgesia, whereas the mice overexpressing
p35 hyperalgesia. Thus, these results clearly establish a
correlation between Cdk5 activity and mechanical
nociception.
Since the discovery of Cdk5, numerous studies have
revealed its multifunctional roles in important physio-
logical processes, such as brain development and
function, neuronal migration, synaptic plasticity, mem-
ory, learning, and neurodegenerative disease processes
[19-23,26,33]. Our previous studies demonstrated that
p35, as well as Cdk5, are expressed in the dorsal root
and the trigeminal ganglia, and that the expression and
activity of Cdk5/p35 is increased during the inflamma-
tion. We and others have also reported that Cdk5 is
required for the basal responses to noxious heat [30,31].
The p35 knockout mice showed delayed responses
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Figure 2 Analysis of the p35 expression profile in p35 knockout mice. The p35 expression levels and Cdk5 activity in the trigeminal ganglia,
brainstem, and brain of the p35 knockout mice: (A) q-PCR analysis revealed significantly decreased levels of p35 mRNA in the trigeminal ganglia,
brainstem, and brain of the p35 knockout mice. Each data set was normalized to the expression seen in control wild-type animals. Results ob-
tained from four different animals are expressed as mean ± SEM and analyzed by an unpaired t-test (***p < 0.001). (B) Representative Western
blots showing p35 protein levels from p35 knockout mice together with corresponding, densitometric analysis. Data were normalized to the
levels of p35 in wild-type controls, and are presented as mean ± SEM (unpaired t-test, ***< 0.001). (C) Cdk5 activity in the trigeminal ganglia, brain-
stem, and brain of the p35 knockout mice. Data are presented as mean ± SEM and analyzed by an unpaired t-test (**p < 0.01, ***p < 0.001).
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Figure 3 Licking responses of Tgp35 mice during the orofacial operant assay. During the testing, the animals accessed the reward by
inserting their snout through the plates with different number of wires. This was done in order to apply different force levels to the animal
vibrissal pad. The number of beam breaks during the acquisition of the reward together with the licking time was measured: (A) without any
stimulation, (B) using the plate with 6 + 6 wires, (C) 9 + 9 wires, and (D) 13 + 13 wires. Data are presented as mean ± SEM from four different
animals measured five times in case of the baseline and three times after the induction of the trigeminal nociception (unpaired t-test,
***p < 0.001). Two sample traces show the automatic recordings of drinking behavior in a testing period of 20 minutes in a single control
(upper trace) and single Tgp35 mouse (lower trace).
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mal stimulation at the hind paws and tail. Moreover, the
inhibition of Cdk5 activity in the cultured DRG neurons
attenuates the capsaicin evoked calcium influx, thus in-
dicating a close link between Cdk5 and TRPV1 [30].
This link was further confirmed using the nociceptor-specific Cdk5 conditional knockout mice, which developed
thermal hypoalgesia associated with reduced phosphoryl-
ation of TRPV1 [30]. In the current study, we extended
our analysis to the role of Cdk5 in orofacial pain.
There are several animal models for studying the dif-
ferent types of pain; whether acute or chronic. Despite
Figure 4 Licking responses of the p35 knockout mice during the orofacial operant assay. During the testing, the animals accessed the
reward by inserting their snout through the plates with the different number of wires, in order to apply different force levels to the animal
vibrissal pad. The number of beam breaks during the acquisition of the reward together with the licking time was measured: (A) without any
stimulation, (B) using the plate with 6 + 6 wires, (C) 9 + 9 wires, and (D) 13 + 13. The data are expressed as mean ± SEM from four different
animals, measured five times in case of the baseline, and three times after induction of the trigeminal nociception (unpaired t-test, ***p < 0.001).
Two sample traces show the automatic recordings of drinking behavior in a testing period of 20 minutes in a single control (upper trace) and
single p35 knockout mouse (lower trace).
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orofacial pain, especially in mice. The majority of the be-
havioral pain tests in the orofacial area are based on
pain-related spontaneous behavior. All these tests induce
the pain by an injection of various chemicals (formalin,carrageenan, or capsaicin) into the upper lip or the
vibrissal pad, and observe licking or grooming behavior.
Recent studies use a mouse grimace scale for the meas-
urement of short term nociception [34] or a device
that quantifies a gnawing function in the mouse [35].
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cial pain have many limitations, including variation in
subjective observations, inability to escape from a nox-
ious stimulus, and the induction of stress in the test
animal. All of these can cause a large variation in the
measured results.
The operant behavioral assay developed and intro-
duced by Neubert in 2005 [16] shows that use of a
reward-aversion paradigm offers more benefits. This
model is based on the reward-conflict paradigm, where
the test animal can decide between receiving a reward,
or it can escape from the aversive stimulus by which it
can control and modify its own behavior. Therefore, as
compared to the other orofacial behavioral tests the use
of this operant assay reduces the stress in the testing an-
imals, there is a possibility to provide the multiple mea-
surements using the same animal, and most importantly,
it is free from investigator bias when it comes to evaluat-
ing the results that are recorded automatically. To the
best of our knowledge, there is no reported study using
orofacial mechanical stimulation test in mice, and we be-
lieve our present study will fill this void.
Although there are many common features in pain
transduction and processing in the trigeminal and spinal
systems, there are key differences in the anatomical and
functional features of the primary afferent neurons of
the trigeminal ganglia that distinguish them from neu-
rons of the spinal dorsal root ganglia. Recent studies
have shown that not only anatomical, but also electro-
physiological and pharmacological differences [36-38] of
the trigeminal afferents innervating unique target tissues
such as meninges, cornea, teeth, oral/nasal mucosa, and
the temporomandibular joint. These differences are con-
sistent with our observations. It has been reported that the
intrathecal administration of roscovitine, a Cdk5 inhibitor,
inhibited Cdk5 activity and attenuated a formalin-induced
nociceptive response in rats [39]. However, we did not ob-
serve any changes in trigeminal p35 mRNA and protein
levels, nor in the Cdk5 activity after the vibrissal formalin
injection (data not shown), thus supporting the theory
about the differential regulation of nociception at the per-
iphery and in the vibrissal pad.
We do not know the precise molecular mechanism by
which Cdk5 activity can affect the orofacial nociception.
There are several possibilities. First, the activation of the
TRPV1 channel by Cdk5-mediated phosphorylation
could participate in this mechanism. The TRPV1 recep-
tor, consistent with its role as a pain regulator, is
expressed in the peripheral and central nervous systems
involved in pain detection, transmission, and regulation.
Phosphorylation and dephosphorylation reactions regu-
late TRPV1 receptor activity, which is crucial in promot-
ing inflammatory pain [40,41]. There is clear evidence
that the TRPV1 channel activation at the periphery isinvolved in the development of inflammatory thermal
hyperalgesia and heat sensitivity [42]. We have also pre-
viously reported that Cdk5 modulates thermal, nocicep-
tive signaling through the phosphorylation of TRPV1 at
threonine-407 [30]. Another recent study points out that
Cdk5 can control TRPV1 membrane trafficking, and
thus regulate the heat sensitivity of the nociceptors [43].
Furthermore, the systemic or intrathecal administration
of TRPV1 antagonists is effective in reducing both ther-
mal hyperalgesia, as well as mechanical allodynia associ-
ated with chronic or neuropathic pain [44-46], which
indicates that TRPV1 could play an important role in in-
tegrating multiple pain-producing stimuli. More recent
studies have uncovered the involvement of TRPV1 in
the central mechanical nociception together in connec-
tion with the other TRP channel – TRPA1 [47]. Other
studies speculate that the central mechanical hyperalge-
sia could be induced by the functional interaction be-
tween P2X3 [48] or NMDA receptor [49] and TRPV1.
These studies provide the evidence that TRPV1 channels
are important not only for the peripheral pain sensation,
but they can also play an important role in the central
mechanical nociception.
An interesting possibility is that Cdk5 can mediate
orofacial mechanical hyperalgesia through the regulation
of the neurotransmitter release, thus indicating that this
kinase could be an important presynaptic control par-
ameter. Deregulation of its activity could affect nocicep-
tion via the presynaptic mechanism with the subsequent
initiation of the pain sensation [50-52]. Another possibil-
ity is that Cdk5 could mediate the orofacial mechanical
hyperalgesia through the activation of other potential
mechanotransducers. It is well known that the upregula-
tion of Cdk5 activity can lead to phosphorylation of delta
opioid receptor [53,54], NMDA receptor [55,56], P2X3
receptor [57], and voltage gated calcium channels [58].
Additionally, there are other potential candidates like
TRPA1 [59-61] or TREK channels [62,63] that contain
the Cdk5 phosphorylation consensus sequence and may
be involved in the Cdk5-mediated activation and
mechanotransduction in the orofacial area. To under-
stand the precise mechanism through which Cdk5 regu-
lates orofacial mechanosensitisation will require further
studies; including molecular, electrophysiological, and
behavioral methods to map the functional role of Cdk5
in this type of the nociception.
Conclusions
We have adapted orofacial stimulation test for mice that
could be used for orofacial pain studies, and using this
test we have identified that Cdk5 activity has an import-
ant role in orofacial mechanical nociception. Moreover,
our studies also demonstrate that genetically engineered
mice with the altered Cdk5/p35 levels will prove to be
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The p35−/− mice and the age-matched, wild-type con-
trols were maintained in C57BL6/129SVJ background.
Tgp35 mice and the wild-type littermate controls were
maintained in FVBN background. All of the animals
were housed and bred in standard cages, and they were
maintained in climate and light controlled rooms with
free access to food and water in accordance with the
U.S. National Institutes of Health Guide for Care and
Use of Laboratory Animals. All of the experiments
adhered to the guidelines of the IASP Committee for
Research and Ethical Issue [64].
Rotarod test
The p35−/− and Tgp35 mice were evaluated for motor
abilities, coordination, and balance by performance on
the rotarod (Model 7650, Ugo Basile, Italy). This instru-
ment consists of a platform under a rotating cylinder
that can be set either to accelerate from 4 to 40 rpm in
the defined period of time or used at a constant speed.
The automated rotarod system has a timer linked to the
platform panel onto which the mouse falls (approxi-
mately 15 cm below the rotating cylinder). During the
testing, the animals have to continuously walk forward
to keep from falling off the rotating cylinder. After the
mice became familiarized with this procedure, they were
placed on the rotating cylinder, and the time until the
animal fell down was measured in three different tests
performed on three consecutive days.
Open field test
Anxiety, exploratory activity, as well as spontaneous
motor activity were evaluated using the VersaMax
Animal activity monitoring system (AccuScan Instru-
ments Inc., Columbus, OH, USA). The testing instru-
ment consists of a clear, plexiglass, rectangular cage
(42 × 42 × 30 cm), with the transparent side wall. Two
sets of sixteen photocells are aligned from the front to
back of the cage and from side to side for recording
horizontal activity. Vertical activity is assessed by an
additional sixteen photocells located above the horizon-
tal cells. The mice were placed individually in the center
of the open field apparatus, and their behavior was mon-
itored for ten minutes. Horizontal or vertical activity
(rearing measured by counting the number of beam in-
terruptions), time spent in the center area of the open
field, and stereotypic counts were automatically recorded
using the VersaMax software system.Mouse orofacial stimulation test
Using a small plastic reducer, we have modified the
Orofacial Stimulation Test (31300, Ugo Basile, Italy),
which was previously used only for the measurement of
hypersensitivity to thermal or mechanical stimulation of
the trigeminal area in rats, and adapted it for assessing
behavioral responses to mechanical stimulation in mice
(Additional file 1C).
An orofacial stimulation test consists of several parts -
the plastic cage (26.5 cm wide, 20 cm deep, and 48 cm
long) with the interface wall containing a drinking win-
dow (1.5 cm wide × 2 cm high) that allows a mouse an
access to a reward; an infrared photo beam built on the
exterior aspect of the window linked to the ORO soft-
ware that automatically quantifies feeding behavior by
measuring the number of attempts the animals made to
acquire the reward, and the total duration of feeding
time (Additional file 1A). The equipment is supple-
mented with metal inserts containing a different number
and configuration of the Nitinol wires (0,155 mm) uti-
lized to induce varying degrees of trigeminal, mechanical
nociception (Additional file 1B). Each of these metal in-
serts can be mounted onto the opposite aspect of the
drinking window with six screws.
During the orofacial operant assay, the test mouse in-
serts its snout through the drinking window in the inter-
face wall to access a nozzle of the bottle containing reward
(30% sucrose) [65]. Simultaneously, while accessing the
nozzle, the mouse breaks an analog output from the infra-
red detectors (Banner Engineering, Minneapolis, MN,
USA) placed directly behind the drinking window, and
thus its attempts to get the reward can be recorded and
analyzed with the ORO software (Additional file 1D).
The mice were deprived of food and water for at least
a period of eight hours prior to the testing sessions,
which was done to increase the incentive for reward ac-
quisition. After the completion of tests, access for food
and water was restored. The mice were trained and
tested in the same cage and at the same time each day,
and they had a day of rest between the testing.
Initially, the animals were trained to access the reward
through the blank plate (without the wires). For mech-
anical testing, access to the reward was impeded by
inserting the plate with the different number of the wires
providing mechanical contact with the vibrissal pad re-
gion of the tested animal (Additional file 1D). We used
three different plates with 6 + 6, 9 + 9, or 13 + 13 wires at
each side in order to apply a different level of mechan-
ical force to the animal vibrissal pad, so as to induce dif-
ferent degrees of pain. After completing five, different,
twenty-minute training sessions, the animals were
retested three times using each plate with a different
number of wires, in increasing order, starting with the
lowest to the highest number of wires. The outcome
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sisted of the total duration of time the test mouse spent
acquiring the reward over a twenty minute period of
time, with or without (baseline measurements) mechan-
ical stimulators and the number of attempts the test
mouse made to access the reward. Both were determined
automatically by an interruption of an infrared beam
when the animal placed its snout through the opening in
the interface wall.
Quantitative real-time PCR (q-PCR)
The trigeminal ganglia, brainstem, and the brain were
dissected out from p35−/−, Tgp35, and wild-type control
mice and these tissues were immediately frozen at
−80°C. The total RNA was extracted using the RNeasy
Mini Kit (Qiagen, Valencia, CA, and USA), according to
the manufacturer’s instructions. The purity of the RNA
was assessed by the ratio of absorbance at 260 nm and
280 nm. The RNA from each sample was reverse tran-
scribed using a High Capacity cDNA Reverse Transcrip-
tion Kit (Applied Biosystems, Foster City, CA, USA).
The q-PCR reactions were conducted using cDNA,
specific primers (Assays on Demand Gene Expression
Products), and TaqMan Universal PCR Master Mix
(Applied Biosystems, Foster City, CA, USA), and they
were run in duplicates using the Real-time PCR System
7500 (Applied Biosystems, Foster City, CA, USA). The
p35 mRNA levels were normalized to the levels of HPRT
using the comparative cycle threshold (ct) method.
Antibodies
Anti-p35 (C19), Anti-Cdk5 (C8) and secondary horse-
radish peroxidase-conjugated anti-mouse and anti-rabbit
antibodies were obtained from Santa Cruz Biotechnology
(Santa Cruz Biotechnology, Santa Cruz, CA, USA). The
anti α-tubulin antibody was purchased from Sigma
Aldrich (Sigma-Aldrich, St. Louis, MO, USA).
Western blotting
The tissue homogenates were lysed in tissue protein ex-
traction reagent (Thermo Scientific, Rockford, IL, USA)
containing a cocktail of protease (Complete Mini, Roche,
Indianapolis, IN, USA) and phosphatase (PhosSTOP,
Roche, Indianapolis, IN, USA) inhibitors to avoid deg-
radation of the proteins. After thirty minutes of incuba-
tion on ice, the samples were spun down at 14000 rpm
at 4°C for 30 min. The supernatant was assayed for
total protein concentration using the Bradford Protein
Assay (Bio-Rad, Hercules, CA, USA). The proteins were
denatured by boiling them with NuPAGE LDS sample
buffer and NuPAGE sample reducing agent (Invitrogen,
Carlsbad, CA, USA) for 10 min. Each sample was sepa-
rated by 4-12% SDS PAGE gels (Invitrogen, Carlsbad,
CA, USA) and transferred to 0.45 μm nitrocellulosemembrane (Invitrogen, Carlsbad, CA, USA). The blots
were blocked for 1 h in phosphate buffered saline con-
taining 5% nonfat dry milk and 0.05% Tween20 (Sigma-
Aldrich, St. Louis, MO, USA), and then they were blot-
ted with primary antibodies overnight at 4°C. The mem-
branes were then probed with horseradish peroxidase-
conjugated anti-mouse or anti-rabbit IgG at room
temperature for one hour, and they were finally developed
by SuperSignal West Pico or Dura Chemiluminescent
Substrate (Thermo Scientific, Rockford, IL, USA). The im-
munoblots were analyzed by densitometry using ImageJ
analysis system software.Immuno-precipitation and Cdk5 activity assay
Immuno-precipitation and Cdk5 kinase activity were
performed as described previously [66]. Briefly, the pro-
tein G (+) A-agarose beads were washed three times
with tris-buffered saline (TBS) and incubated with Cdk5
antibody (1–2 ug/500 ug of protein lysate, Santa Cruz
Biotechnology, Santa Cruz, CA, USA) for 1 h at room
temperature with gentle mixing. The beads were centri-
fuged and washed three times with TBS and then sus-
pended in TBS. The protein lysates from the trigeminal
ganglia, brainstem, and brain were incubated with anti-
body conjugated beads for 2 h and 30 min at 4°C on a
rotating wheel. The beads were subsequently centrifuged
and washed two times with TBS, one time with 1X
kinase buffer and suspended in kinase buffer (50 mM
Tris/HCl pH 7.4, containing 1 mM EGTA, and 5 mM
MgCl2). The immunoprecipitated beads were used as an
enzyme source for the kinase activity. For the kinase
assay, a total volume of 50 μL of kinase assay mixture
was used, containing 50 μM Tris/HCl (pH 7.4) with
EGTA, 1 mM dithiothreitol, 5 mM MgCI2, 10 μg of his-
tone H1, and 10 μL of Cdk5 immunoprecipitates. The
phosphorylation reaction was initiated by the addition of
0.1 mM [γ-32P] ATP and incubated at 30°C for one hour.
The reaction was stopped by the addition of the
Laemmli sample buffer. The reaction mixture was
heated for five minutes at 90°C and electrophoresed on a
4-20% SDS-PAGE gel stained with Coomassie blue, and
then dried and exposed overnight for the detection of
32P-labeled Histone H1 by autoradiography. The films
were scanned, and the bands were quantified using Ima-
geJ software.Statistical analysis
All data are expressed as a mean ± SEM. The statistical
evaluation was done with GraphPad Prism software,
version 5.0 (GraphPad, San Diego, CA, USA). Statistical
differences between the experiments were assessed
by unpaired t-test. The significance level was set at
p < 0.05.
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Additional file 1: Mouse orofacial stimulation test system used for
the measurement of orofacial mechanical nociception. (A) Orofacial
stimulation test device. (B) The mechanical inserts with different number
of wires used for the induction of trigeminal pain. (C) The plastic reducer
used for the modification of the existing system to be applicable for the
characterization of mouse orofacial pain. (D) An example showing the
mouse during the reward licking while its vibrissal region is in direct
contact with the wires.
Additional file 2: Effect of different p35 genotype on locomotor
and exploratory activity. (A) The mean performance time determined
as time spent on the rotating cylinder during the acceleration. (B) The
latency to fall from the rotating cylinder by the constant speed. (C) The
unaffected horizontal and (D) vertical activity as revealed by the open
field test. The data analyzed by the unpaired t-test are expressed as
mean ± SEM and represent the mean from four different animals.
Additional file 3: The effect of upregulated p35 and Cdk5 activity
on mouse behavior in an open-field test. (A) The center distance
travelled and time spent in the center of the activity cage, (B) stereotypy
and the time Tgp35 mice spent with the stereotypic behavior. (C) The
time Tgp35 mice spent in the different parts of the activity cage during
ten minutes of measurement. These values represent the mean ± SEM
from four animals.
Additional file 4: The effect of downregulated p35 and Cdk5
activity on mouse behavior in an open-field test. (A) The center
distance travelled and time spent in the center of the activity cage, (B)
stereotypy and the time p35 knockout mice spent with the stereotypic
behavior. (C) The time p35-/- mice spent in the different parts of the
activity cage during 10 min of measurement. These values represent the
mean ± SEM from four animals.
Abbreviations
Cdk5: Cyclin-dependent kinase 5; TRPV1: Transient receptor potential
vanilloid 1; TG: Trigeminal ganglia; Tgp35: Transgenic p35 mice; p35-/-: p35
knockout mice; q-PCR: Quantitative real-time PCR; WT: Wild-type.
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